"STORM Data Show Encouraging Responses, OS With Selinexor / Dexamethasone In Penta-Refractory Myeloma" -Jason Harris
Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen. The data, which were presented at the 2018 SOHO Annual Meeting, showed that the doublet regimen was associated with an overall response rate (ORR) of 26.2 percent and a median overall survival (OS) of 8.6 months in patients with penta-refractory disease. Sundar Jagannath, MD, MBBS, professor of medicine, hematology and medical oncology, and director of the Myeloma Program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, delivered the STORM findings during the meeting. He added that patients who had a response to treatment, even a minor response, did significantly better with an OS of 15.6 months. Historically, the median OS in this patient population is an estimated 3.6 months. “When patients relapse, it is a real challenge to manage,” he said. “There are no approved drugs established for this patient population.”
- Sundar Jagannath, MD, MBBS, Professor, Medicine, Hematology, Medical Oncology, Director, Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage:
Targeted Oncology
Future Breast Imaging and Biopsy Are Not Eliminated After Mastectomy
Oct 09, 2018 View All Press Releases